United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $313.91, for a total value of $1,130,076.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $40,808.30. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Price Performance

UTHR stock opened at $319.04 on Wednesday. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $321.80. The stock’s fifty day simple moving average is $269.89 and its 200-day simple moving average is $242.53. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $14.15 billion, a price-to-earnings ratio of 15.08, a price-to-earnings-growth ratio of 4.74 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. During the same quarter last year, the firm earned $4.86 earnings per share. The business’s revenue was up 33.7% on a year-over-year basis. Equities research analysts expect that United Therapeutics Co. will post 24.42 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently made changes to their positions in UTHR. Rise Advisors LLC acquired a new stake in shares of United Therapeutics during the first quarter worth $32,000. GAMMA Investing LLC acquired a new position in United Therapeutics in the fourth quarter valued at $43,000. Benjamin F. Edwards & Company Inc. boosted its holdings in United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 117 shares during the last quarter. Janiczek Wealth Management LLC boosted its holdings in United Therapeutics by 21.1% in the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 84 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in United Therapeutics by 10.0% in the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 46 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. The Goldman Sachs Group raised their price objective on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Oppenheimer raised their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 20th. HC Wainwright reiterated a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. increased their target price on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, May 21st. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $312.22.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.